Citations

Clear

38 citation(s) found for "Orenstein, Robert".

Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
Lee, Christine H. , Orenstein, Robert , Khanna, Sahil , Hecht, Gail , Gerding, Dale N. , Dubberke, Erik R.

Mayo Clinic

Clinical Infectious Diseases | March 28, 2018 | Volume: 67 | Issue: 8 | Pages: 1198-1204

10.1093/cid/ciy259 | PMID 29617739 Get It

Tetracyclines are Associated with a Reduced Risk of Clostridium difficile Infection: A Systematic Review and Meta-analysis
Cho, Janice , Kapoor, Saloni , Orenstein, Robert , Singh, Siddharth , Pardi, Darrell S. , Khanna, Sahil , Tariq, Raseen

Mayo Clinic

Open Forum Infectious Diseases | October 4, 2017 | Volume: 4 | Issue: suppl_1 | Pages: S384-S384

10.1093/ofid/ofx163.953 Get It

Abstract Background Efforts towards antibiotic stewardship help reduce risk of Clostridium difficile infection (CDI) but there is a need to delineate antibiotic choices to reduce CDI risk. Tetracyclines may be associated with a low risk for CDI but the evidence is conflicting. We conducted a systematic review and meta-analysis to determine the relationship between tetracyclines use and CDI. Methods A systematic search of Medline, Embase, and Web of Science was performed from January 1978 up to December 2016 including studies assessing the association between tetracyclines and CDI; compared with other antibiotics; to assess the risk of CDI after exposure to tetracyclines vs. other antibiotics. Study quality was assessed using the Newcastle-Ottawa scale. Weighted summary estimates were calculated using generalized inverse variance with random-effects model using Review Manager version 5.3 (Cochran Inc). Results Six studies; 4 case control and 2 cohort studies reported the association of CDI with tetracyclines or other antibiotics prior to CDI including patients from 1993 to 2012. Meta-analysis of all studies using the random-effects model demonstrated that tetracyclines were associated with decreased risk of CDI compared with other antibiotics (OR, 0.62; 95% CI, 0.47–0.81; P = .0005). There was significant heterogeneity among the studies, with an I2 of 53% (Figure 1). No publication bias was seen. Subgroup analysis of studies evaluating the risk of CDI with doxycycline only also demonstrated a decreased risk of CDI with doxycycline compared with other antibiotics (OR, 0.55; 95% CI, 0.40–0.75; P = 0.0002). A subgroup analysis based on CDI diagnosis definitions revealed a decreased risk of CDI with tetracyclines (OR, 0.59; 95% CI, 0.44–0.80; P = 0. 0006) in studies that used clinical definitions (presence of diarrhea with a positive stool test), but not among the studies that used ICD-9 codes for CDI diagnosis (OR, 0.95; 95% CI, 0.45–2.01; P = 0.90). Conclusion Tetracyclines are associated with a lower risk of developing CDI compared with other antibiotics. It is reasonable to use these over other antibiotics when appropriate (community acquired pneumonia, bronchitis, chlamydia, rickettsial or spirochetal infections) to reduce the risk of CDI. Forest plot demonstrating decreased odds of CDI with tetracyclines use by a random-effects model Disclosures All authors: No reported disclosures.
1799Next Generation Fecal Transplant for Recurrent C. difficile Infection with and without Antiobiotic Pre-Treatment: Lessons Learned from the PUNCH CD Phase 2 Safety Study
Mariani, P., Price, Connie, Orenstein, Robert , Harris, H. L., Sobcinski, Mary Kay

Mayo Clinic

Open Forum Infectious Diseases | February 2, 2017 | Volume: 1 | Issue: suppl_1 | Pages: S62-S63

10.1093/ofid/ofu051.171 Get It

Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results. of the PUNCH CD 2 Trial
Lee, Christine , Orenstein, Robert , Khanna, Sahil , Hecht, Gail , Fraiz, Joseph, Dubberke, Erik R. , Lee, Christine H.

Mayo Clinic

Open Forum Infectious Diseases | February 1, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.1044 Get It

Factors Associated With Clostridium difficile Infection Relapse in Patients After Fecal Microbiota Transplant
Hartmann, Carlos, Allen, Sorcha , Griesbach, Cheryl L., Orenstein, Robert , Patron, Roberto L. , Kosiorek, Heidi

Mayo Clinic

Open Forum Infectious Diseases | February 1, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available

10.1093/ofid/ofw172.1665 Get It

1657Who Seeks a Fecal Microbiota Transplant for Recurrent C. difficile Infection?: Patient Profile of the PUNCH CD Study
Orenstein, Robert , Griesbach, Cheryl L., Sobcinski, Mary Kay, Dubberke, Erik R.

Mayo Clinic

Open Forum Infectious Diseases | February 1, 2017 | Volume: 1 | Issue: suppl_1 | Pages: S443-S443

10.1093/ofid/ofu052.1203 Get It

The Journal of the American Osteopathic Association: The Next Generation
Orenstein, Robert

Mayo Clinic

Journal of Osteopathic Medicine | April 21, 2014 | Volume: 114 | Issue: 5 | Pages: 332-333

10.7556/jaoa.2014.065 | PMID 24777994 Get It

Melarsoprol-associated multifocal inflammatory CNS illness in African trypanosomiasis
Orenstein, Robert , Uslan, Daniel Z. , Berbari, Elie F. , Klein, Christopher J. , Windebank, Anthony J. , Kumar, Naveen , Klein, Christopher J

Mayo Clinic

Neurology | March 16, 2006 | Volume: 66 | Issue: 7 | Pages: 1120-1121

10.1212/01.wnl.0000202519.59577.4c | PMID 16540605 Get It